Why There Are No Settlements Yet
The Depo-Provera meningioma litigation is in its early stages. The first lawsuit was filed in October 2024, and MDL 3140 was established in February 2025. Rule 702 hearings on general causation are scheduled for late May 2026. No manufacturer has made a global settlement offer.
Projected Settlement Ranges
Based on comparable pharmaceutical brain tumor and neurological injury litigation: Tier 1 (meningioma managed without surgery) projects $75,000–$200,000; Tier 2 (meningioma requiring craniotomy) projects $200,000–$600,000; Tier 3 (permanent neurological damage or recurrence) projects $600,000–$1,500,000+.
Comparable Mass Tort Settlements
The NuvaRing settlement ($100M for ~3,800 claims), Mirena IUD verdict ($12.2M individual), Elmiron vision loss bellwether verdict ($54.5M), and Depakote birth defect verdict ($15M) provide relevant benchmarks for pharmaceutical injury claims with similar failure-to-warn theories.
When Will Settlements Happen?
Settlement negotiations typically begin after bellwether trial outcomes. Rule 702 hearings in May 2026 will first determine whether plaintiffs' general causation experts can testify. If the science survives Daubert challenges, settlement pressure on Pfizer increases significantly. Filing now ensures your case is in the MDL pipeline when negotiations begin.
Scientific Evidence
Medroxyprogesterone Acetate and Meningioma: A Global Issue
Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health
View on PubMed→Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma
Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ
View on PubMed→The Association between Medroxyprogesterone Acetate Exposure and Meningioma
Griffin BR et al. (2024). Cancers
View on PubMed→Frequently Asked Questions
Related Pages
Depo-Provera Meningioma Brain Tumor
Meningioma — a tumor in the tissue surrounding the brain — is the primary injury in Depo-Provera lawsuits. Studies show long-term users face up to a 5.6x increased risk. The tumor can cause seizures, vision loss, and require major brain surgery.
Depo-Provera Brain Tumor Symptoms
Meningioma symptoms develop gradually and include persistent headaches, vision changes, seizures, and cognitive decline. If you used Depo-Provera and experience these symptoms, request brain imaging from your doctor.
Depo-Provera Long-Term Use Risks
Long-term Depo-Provera use carries multiple serious risks: meningioma brain tumors (up to 5.6x risk), significant bone density loss (black box warning), weight gain, depression, and delayed return to fertility. The FDA recommends limiting use to 2 years.
Pfizer Depo-Provera Lawsuit
Pfizer inherited Depo-Provera when it acquired Pharmacia & Upjohn in 2002. Despite international warnings dating to 2015, Pfizer did not add a U.S. meningioma warning until December 2025. Plaintiffs allege a pattern of delayed safety action prioritizing revenue over patient safety.
Depo-Provera Alternatives After Diagnosis
If you are diagnosed with a meningioma, the FDA recommends discontinuing Depo-Provera immediately. Safer contraceptive alternatives exist that do not carry meningioma risk, including copper IUDs, barrier methods, and non-progestin options.
Depo-Provera Military Veterans
Military women were disproportionately prescribed Depo-Provera due to its convenience for deployment. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may be eligible for both civil lawsuit compensation and VA benefits.
Depo-Provera MRI Screening
Current guidelines do not recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label instructs providers to monitor for meningioma symptoms. If you have symptoms, request brain imaging immediately.
Depo-Provera Brain Tumor Lawsuits Lawsuit
Depo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection administered every three months. Over 2,000 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. Women who received the shot for more than one year face up to a 5.6-fold increased risk, and the risk escalates with duration of use.
View full case overview